Wang He, Chun Wanshun, Hu Mengjie, Zhang Cheng, Mei Zixuan, Gong Cheng, Wu Tiangen, Jiang Ping, Cheng Zhixiang, Liu Zhisu, Pan Dingyu, Yuan Yufeng, Li Zhen
Objective To evaluate the short-term efficacy and safety of gastric bypass stents in the treatment of obesity and metabolic diseases. Methods A total of 40 patients with obesity who underwent gastric bypass stent placement at Zhongnan Hospital of Wuhan University from September 2024 to March 2026 were retrospectively included. All patients were included in the safety analysis, and 35 patients completed the planned 3-month stent indwelling period and were included in the primary efficacy analysis. Body weight changes from preoperative baseline to 1-6 months after surgery were analyzed. Changes in anthropometric measures, glucose and lipid metabolism, liver function, hepatic steatosis (quantitatively assessed by controlled attenuation parameter [CAP]), and nutrition-related indicators were compared between preoperative status and 3 months after surgery. A linear mixed-effects model was used to analyze repeated measures of body weight. Results Body weight at all postoperative time points was significantly lower than preoperative levels (P<0.001). At 3 months after surgery, the percentage of total weight loss(%TWL) was (10.79±3.33)%, and the percentage of excess weight loss (%EWL) was (52.73±27.72)%; at 6 months after surgery, %TWL and %EWL reached (14.51±4.91)% and (73.29±36.19)%, respectively. At 3 months after surgery, body fat percentage, waist circumference, hip circumference, and systolic blood pressure were all significantly reduced (all P<0.05), whereas skeletal muscle percentage was significantly increased(P<0.001). Glycemic indicators, including glycated hemoglobin, fasting blood glucose, fasting insulin, C-peptide, and homeostasis model assessment of insulin resistance, all improved significantly (all P<0.01). CAP and transaminases, including alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase, all decreased significantly (all P<0.001), but there was no statistically significant change in liver stiffness measurement. Total cholesterol and low-density lipoprotein cholesterol decreased significantly (P<0.05), whereas triglycerides and high-density lipoprotein cholesterol showed no significant changes. Serum iron, ferritin, and hemoglobin levels decreased significantly at 3 months after surgery (P<0.05), while vitamin B12, folate, and 25-hydroxyvitamin D showed no obvious changes. In terms of safety, 17 of the 40 patients(42.5%) reported adverse reactions, mainly mild nausea, vomiting, and abdominal pain. In 5 patients (12.5%), the stent was removed early because of serious adverse reactions such as upper gastrointestinal bleeding, severe abdominal pain, or hypocalcemic seizures. No serious adverse events such as liver abscess or perforation occurred. Conclusion Within the 3-month indwelling period, gastric bypass stents can effectively reduce body weight in patients with obesity and improve glucose metabolism, hepatic steatosis, and some lipid parameters; however, overall safety warrants further attention. Monitoring of iron metabolism indicators should also be strengthened. Their long-term efficacy and safety still need to be validated in larger-scale studies with longer follow-up.